xRead - September 2022

Wise et al.

Page 383

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Study Year LOE Study design Study groups Clinical endpoint Conclusion Wakabayashi et al. 1337 2012 1b RCT 1 Pranlukast; 2 Placebo Symptoms Pranlukast reduced symptoms compared to placebo in children with artificial allergen exposure. Day et al. 1338 2008 1b RCT 1 Montelukast; 2 Levocetirizine; 3 Placebo

Symptoms Both montelukast and levocetirizine improved symptoms following artificial allergen exposures. Levocetirizine was more effective than montelukast. Jiang 1348 2006 1b RCT 1 Zafirlukast; 2 Loratadine; 3 Loratadine + pseudoephedrine Symptoms, acoustic rhinometry, rhinomanometry

All treatment groups had a significant reduction of pretreatment symptoms. Zafirlukast was superior at

reduction of nasal congestion. There were no differences in acoustic rhinometry and rhinomanometry between the 3 treatment groups. Mucha et al. 1321 2006 1b RCT 1 Montelukast; 2 Pseudoephedrine Symptoms, QOL, nasal peak inspiratory flow Montelukast and pseudoephedrine had equivalent

improvement of symptoms (except nasal congestion for which pseudoephedrine was more effective), QOL, and nasal peak inspiratory flow. Patel et al. 1339 2005 1b RCT 1 Montelukast; 2 Placebo

Symptoms, QOL Montelukast was more effective than placebo in reducing symptoms and improving QOL in patients with perennial allergic rhinitis Chervinsky et al. 1340 2004 1b RCT 1 Montelukast; 2 Placebo Symptoms, pollen count

Montelukast was more effective than placebo in reducing symptoms. The effect size was related to the amount of pollen exposure. Philip et al. 1341 2004 1b RCT 1 Montelukast; 2 Placebo Symptoms, rhinitis QOL, asthma QOL van Adelsburg et al. 1342 2003 1b RCT 1 Montelukast; 2 Loratadine; 3 Placebo

Montelukast improved symptoms, rhinitis QOL, and asthma QOL compared to placebo in patients with concurrent seasonal allergic rhinitis and asthma. Ratner et al. 1345 2003 1b RCT 1 Montelukast; 2 Fluticasone

Symptoms, QOL Fluticasone was more effective than montelukast in reducing symptoms and improving QOL.

Symptoms, QOL Montelukast was more effective than placebo in reducing symptoms and improving QOL. Montelukast not directly compared to loratadine.

Symptoms, QOL Montelukast was more effective than placebo in reducing symptoms and improving QOL. Montelukast not directly compared to loratadine.

van Adelsburg et al. 1343 2003 1b RCT 1 Montelukast; 2 Loratadine; 3 Placebo

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.